Innate Pharma to present IPH6501 preclinical data at the EHA 2023 congress

IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentation Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET ® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany. ANKET ® is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. Innate’s latest innovation, the tetra-specific ANKET ® , is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and the interleukin-2 receptor (via an non-alpha IL-2 variant, IL-2v) via a single molecule. By providing proliferation and activation signals targeted to NK cells, tetra-specific ANKET ® leverages the advantages of harnessing NK cell effector functions against cancer cells. IPH6501, the first tetra-specific ANKET ® , continues toward a Phase 1 clinical trial in 2023. Presentation details Presentation: S258 Title: IPH6501 is a first-in-class tetraspecific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas Session: s425 Gene therapy and immunotherapy - Biology & translational research Date and time: 10/06/2023, 11:30 - 12:45 Location: Fantasie Speaker: Olivier Demaria, PhD, R&D Director, Science Leader at Innate Pharma Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗